Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation

BACKGROUND: EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20–30 % of EGFR-mutated cases showed no response to EGFR-TKIs, suggesting that other determina...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Su, Xiaomei, Bai, Hua, Zhao, Jun, Duan, Jianchun, An, Tongtong, Zhuo, Minglei, Wang, Zhijie, Wu, Meina, Li, Zhenxiang, Zhu, Jian, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643502/
https://www.ncbi.nlm.nih.gov/pubmed/26563758
http://dx.doi.org/10.1186/s13045-015-0210-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643502/
https://www.ncbi.nlm.nih.gov/pubmed/26563758
http://dx.doi.org/10.1186/s13045-015-0210-9

Ejemplares similares